Intensive Cardiology Care Unit, San Camillo De Lellis Hospital, Manfredonia (FG), Italia.
Expert Opin Pharmacother. 2011 Feb;12(3):443-50. doi: 10.1517/14656566.2011.548321.
published data indicate that heart rate is an independent strong predictor of cardiovascular and all-cause mortality in men and women of all ages, with and without cardiovascular disease, including atherosclerosis, ventricular arrhythmias, and left ventricular dysfunction. Ivabradine is a pure heart-rate-lowering agent with well-documented antianginal and anti-ischemic properties comparable to well-established anti-anginal agents.
this short review explores recent results with ivabradine, a new medication that lowers heart rate by selectively inhibiting the I (f) current. This review also describes future potential applications.
measurement of heart rate represents an important component of the assessment of patients with coronary artery disease and chronic heart failure, and should be viewed in the same light as other risk factors, because a high heart rate has direct detrimental effects not only on myocardial ischemia but also on the progression of atherosclerosis, ventricular arrhythmias and left ventricular function. Ivabradine has anti-ischemic and antianginal efficacy equivalent to that of β-blockers and calcium channel antagonists in the treatment of chronic stable angina pectoris. Recently ivabradine has been shown to improve cardiac outcomes in stable coronary artery disease and left ventricular systolic dysfunction in patients who have heart rates of ≥ 70 bpm and in patients with stable angina.
已发表的数据表明，心率是所有年龄段、无论是否患有心血管疾病（包括动脉粥样硬化、室性心律失常和左心室功能障碍）的男性和女性心血管和全因死亡率的独立强预测因素。伊伐布雷定是一种纯心率降低剂，具有良好的抗心绞痛和抗缺血特性，可与成熟的抗心绞痛药物相媲美。
这篇简短的综述探讨了伊伐布雷定的最新研究结果，伊伐布雷定是一种通过选择性抑制 I(f)电流来降低心率的新型药物。该综述还描述了未来的潜在应用。
心率的测量是评估冠状动脉疾病和慢性心力衰竭患者的重要组成部分，应与其他风险因素同等看待，因为高心率不仅对心肌缺血有直接的不利影响，而且对动脉粥样硬化、室性心律失常和左心室功能的进展也有不利影响。伊伐布雷定在治疗慢性稳定型心绞痛方面具有与β受体阻滞剂和钙通道拮抗剂相当的抗缺血和抗心绞痛疗效。最近的研究表明，伊伐布雷定可改善稳定型冠状动脉疾病和左心室收缩功能障碍患者的心脏结局，这些患者的心率≥70 次/分，且患有稳定型心绞痛。
